Acute kidney injury (AKI) is a commonly encountered clinical syndrome. Although it often
complicates community acquired illness, it is more common in hospitalized patients …

Acute kidney damage (AKI) is a serious and common consequence among critically unwell
individuals. Traditional biomarkers, such as serum creatinine, frequently fail to detect AKI in …

Background Cisplatin is associated with acute kidney injury (AKI) and electrolyte
abnormalities. Urine tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth …

Early kidney injury may be detected by urinary markers, such as beta-2 microglobulin (B2M),
tissue inhibitor of metalloproteinases-2 (TIMP-2), insulin-like growth factor-binding protein 7 …

The tissue inhibitor of metalloproteinases 2 (TIMP2) has emerged as a promising biomarker
for predicting the risk of sepsis-associated acute kidney injury (SA-AKI). However, its exact …

Approximately 60% of septic patients developed acute kidney injury (AKI). The mortality rate
of septic AKI (SA-AKI) is two to three times higher than that of septic without AKI (SA-non …

Rationale Because acute kidney injury (AKI) is closely related to poor prognosis in critically
ill patients, developing biomarkers for its prediction and early diagnosis is particularly …

Objective (s) Acute kidney injury (AKI) is defined and staged by reduced urine output (UO)
and increased serum creatinine (SCr). UO is typically measured manually and documented …

Objective This article describes the statistical analysis plan for the Biomarker-guided
intervention to prevent AKI after major surgery (BigpAK-2) trial. Design Adaptive trial design …

Diagnostic and prognostic values of Kruppel-like factor 5 (KLF5) and Runt-related
transcription factor 1 (RUNX1) were determined in sepsis-induced acute kidney injury (SI …